2003 Disease Research Vaccine 
Drug Discovery World
MAY 15, 2024
Researchers have developed a new vaccine technology that can provide protection against a broad range of coronaviruses with potential for future disease outbreaks – including ones we don’t know about yet. Building protective vaccines before a pandemic emerges “We don’t have to wait for new coronaviruses to emerge.
The Pharma Data
OCTOBER 18, 2021
Northwestern Medicine scientists have shown for the first time that coronavirus vaccines and prior coronavirus infections can provide broad immunity against other, similar coronaviruses. The findings build a rationale for universal coronavirus vaccines that could prove useful in the face of future epidemics.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JULY 22, 2021
NOTE: ADUHELM TM (aducanumab-avwa)injection 100 mg/mL solutionis indicated for the treatment of Alzheimer’s disease. Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. Biogen Inc.
PLOS: DNA Science
JULY 27, 2023
That information led, thanks to vaccine shelved from the first SARS circa 2003, to the rapid development and deployment of mRNA vaccines against the new infectious disease. I tracked the numbers of sequenced SARS-CoV-2 genomes posted at GISAID every few days during the pandemic, contributed by researchers everywhere.
NIH Director's Blog: Drug Development
MAY 21, 2020
Science, 2020 We now know that the immune system of nearly everyone who recovers from COVID-19 produces antibodies against SARS-CoV-2, the novel coronavirus that causes this easily transmitted respiratory disease [1]. They were then able to produce many identical copies of each antibody, referred to as monoclonal antibodies.
The Pharma Data
MARCH 26, 2021
It causes inflammation in the kidneys and can lead to end-stage kidney disease which may require dialysis or a transplant. 2] LN can lead to end-stage kidney disease, which requires kidney dialysis or a transplant. Approximately 20% of patients with LN progress to end-stage kidney disease within 10 years of diagnosis. [5].
NIH Director's Blog: Drug Development
MARCH 18, 2021
He uses these fundamental insights to guide the design of vaccines and therapeutics, including promising monoclonal antibodies. More importantly for Veesler’s research, bats host a wide range of viruses—more than any other mammal species. But Veesler doesn’t consider himself a visionary by expanding his research to bats.
Expert insights. Personalized for you.
130 
Let's personalize your content